BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment...
BIOCORRX INC NEW (BICX)
NASDAQ:AMEX Investor Relations:
ir.biocorrx.com
Company Research
Source: Yahoo! Finance
treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number U01DA059994 for the development of BICX104, a subcutaneous, long-duration naltrexone implantable pellet, alone or in conjunction with bupropion for the treatment of methamphetamine use disorder (MUD). Clinical studies have supported the use of naltrexone in the treatment of MUD, as well as the combination of naltrexone with bupropion to significantly reduce the use of methamphetamines. The number of people meeting the criteria for MUD, and methamphetamine-involved overdose deaths and arrests, increased from 2015 to 2019 according to a secondary data analysis by Pew , which shows that arrests for meth possession during this period increased by 59%. Data reported by NSDUH and CDC showed a
Show less
Read more
Impact Snapshot
Event Time:
BICX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BICX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BICX alerts
High impacting BIOCORRX INC NEW news events
Weekly update
A roundup of the hottest topics
BICX
News
- BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia [Yahoo! Finance]Yahoo! Finance
- BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and SchizophreniaGlobeNewswire
- BioCorRx Reports Business Update for 2023 [Yahoo! Finance]Yahoo! Finance
- BioCorRx Reports Business Update for 2023GlobeNewswire
- BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUDGlobeNewswire
BICX
Sec Filings
- 5/1/24 - Form 4
- 4/5/24 - Form 4
- 4/3/24 - Form 8-K
- BICX's page on the SEC website